Menu
Primary Navigation
–
Pages, Posts & Categories
Home
Posts
Psychedelic websites & blogs
14. October 2022
The role of Indigenous knowledges in psychedelic science
23. January 2022
Ayahuasca & CogPsy
23. January 2022
Psilocybe induced rejuvenation (Reddit)
14. January 2022
Gilgamesh and the Magic Plant
30. December 2021
Ueber Pellote – Ein Beitrag zur pharmakologischen Kenntniss der Cacteen
29. December 2021
Psilocybin study enrolls clinicians with COVID-linked blues
29. December 2021
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects
26. December 2021
The subjective experience of acute, experimentally-induced Salvia divinorum inebriation
26. December 2021
Identification of a novel member of the family Betaflexiviridae from the hallucinogenic plant Salvia divinorum
26. December 2021
Salvia divinorum: from recreational hallucinogenic use to analgesic and anti-inflammatory action
26. December 2021
Chemical syntheses of the salvinorin chemotype of KOR agonist
26. December 2021
Salvia divinorum increases alcohol intake and tonic immobility whilst decreasing food intake in Wistar rats
26. December 2021
Sociological investigations of human enhancement drugs: The case of microdosing psychedelics
26. December 2021
Tactics of Legitimation in the Psychedelic Sciences: Lessons for Feminist Sociology of Knowledge
26. December 2021
The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies
25. December 2021
Schopenhauer on death (Thanatology)
25. December 2021
Arthur Schopenhauer and psychiatry 200 years after the publication of The World as Will and Representation
24. December 2021
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
22. December 2021
The Therapeutic Potential of Psilocybin
22. December 2021
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
21. December 2021
5-Methoxy- and 5-Hydroxyindoles in the skin of Bufo alvarius
19. December 2021
Ayahuasca-Tourismus in Peru: Motivationen und subjektive Bedeutungen bei Teilnehmern von Ayahuasca-Retreats im oberen Amazonasgebiet
19. December 2021
The personal experiences of ayahuasca brew users as a therapeutic catalyst for substance dependence: A qualitative exploratory approach
19. December 2021
Exploring the effect of Trichocereus pachanoi on the depression-like behavior in rats
17. December 2021
Mescalina y ritual del cactus de san Pedro: evidencias arqueológicas y etnográficas en el norte de Perú
17. December 2021
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects
15. December 2021
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
15. December 2021
DMT Models the Near-Death Experience
15. December 2021
Neural correlates of the DMT experience assessed with multivariate EEG
15. December 2021
Fractal in HTML & CSS
15. December 2021
Bioactive Components of Salvia and Their Potential Antidiabetic Properties: A Review
15. December 2021
Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT)
14. December 2021
Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
14. December 2021
Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
14. December 2021
Tabernanthalog—a water-soluble, non-hallucinogenic, non-toxic analogue of ibogaine
11. December 2021
Newtonian fractal
11. December 2021
A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future
10. December 2021
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution (Peprint)
10. December 2021
Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention
10. December 2021
The Evolved Psychology of Psychedelic Set and Setting: Inferences Regarding the Roles of Shamanism and Entheogenic Ecopsychology
10. December 2021
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
10. December 2021
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers
10. December 2021
5-Hydroxytryptamine and Intestinal Flora on Depressive-Like Behavior Induced by Lead Exposure in Rats
6. December 2021
Serotonin, fearfulness, dominance, and trainability in horses
6. December 2021
Serotonin and cancer
6. December 2021
Serotonin, dopamin and orgasm
6. December 2021
The use of Psilocybin in oncology
3. December 2021
Psilocybin for the treatment of bipolar depression: A review
3. December 2021
Psychedelic (R)Evolution
3. December 2021
Psilocybin induces dendritic spine formation
3. December 2021
Psilocybin & Genetic Ageing
28. November 2021
Slide
Pages
Psychedelics & Shadow-work
Home
Contact
Psychedelic Webdesign
Bitcoin TradingView Widget
Etymology of the term psychedelic
Post with image
Psychedelic companies
JCU
Sir Arthur Eddingtons parabel of the ichthyologist
Psychedelic web-projects
Sir Arthur Eddington: The Philosophy of Physical Science (1938)
Clinical Trails
References 2021
The world is a psychedelic lab (animation)
Clinical trials with psychedelics in 2021
Psilocybin patents
Psilocybin & depression
5-methoxy-N,N-dimethyltryptamine: An ego-dissolving neurochemical catalyst of creativity
Credits
Dataprotection & Legal Disclaimer
Lectures & Presentations
WikiGalaxy
Interactive generative art
Cosmic symbolism
References for psychedelic therapy network
Test DHTML sidebar
Animated Psychedelic-Lab SVG logo
Post overview (list format)
Psychedelics & Fractals
Sitemap
Psychedelic stock watchlist
Psychonautic & Cybernetic
DMT case report (Strassman, 2001)
DMT patents
Psilocybin patent fillings
MDMA patents
Psychedelic Unselfing and Moral Perception (Master thesis)
Psychedelic Collage
Contact form
Meditation – Yoga Nidra
Random Quotes
Neuromodulatory effects of psychedelics: An interactive visual synopsis
Mindmap – Transdisciplinary psychedelic science
Psychedelics and awareness
Psyche & Chronos: Psychedelics and phenomenological time perception
☸️ Mandukya Upanishad
Psychedelics & Cybernetics
Intelligent design
Substances used in project Bluebird, Artichoke, MK-Ultra, and MK-Delta
Putnams “Brain in a vat” (solipsism, naive realism, skepticism and content externalism)
The search for the manchurian candidate
Inner and outer dimensions
Transcending academic and epistemic boundaries: Psychoactive tryptamines and the frontiers of human exploration
Slide
Categories
5-MeO-DMT
Ayahuasca
DMT
Iboga
Media
Mescaline
Psilocybin/Psilocin
Psychdelic Webdesign
Salvia
Varia
Slide
Current location
–
Breadcrumb trail
Path:
Home
/
Bitcoin TradingView Widget
RSS News Feed
–
Dynamically generated updates
Slide
Israel Isn’t a Leader in Psychedelic Healing - It’s an Apartheid State
How I Ease my OCD and Anxiety with Psychedelics
8 Songs for Transformational Psychedelic Mushroom Experiences
How Psychedelic Mushrooms Support Me
Q4 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Big, if True: Did Australia Legalize MDMA and Psilocybin?
Statement: Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme
FDA Provides Additional Guidance for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
MDMA Therapy Training Program Update: January 2023
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
Give the Gift of Healing: Donate to Psychedelic Therapy this December 2022
FDA Continues Clinical Hold for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Policy and Advocacy Update: December 2022
MDMA Therapy Training Program Update: December 2022
Slide
Israel Isn’t a Leader in Psychedelic Healing - It’s an Apartheid State
Israel Isn’t a Leader in Psychedelic Healing - It’s an Apartheid State
Publication date: 05-15-2020
Open full article in lightbox
Art by Nikolitsa Paranomos. Image description: Psychedelic blue and white background over the apartheid wall with Palestinian resistance art that reads, “to exist is to resist.” By Amanda GelenderIsrael has recently been featured , heralded as a leader for its investment in psychedelic clinical trials for MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD). Israel is the first national government to approve MDMA as part of a “Compassionate Use” program, which allows people to use clinically unproven treatments because their suffering is so severe and unresponsive to available medical interventions. The clinical trials enlist Israelis suffering from PTSD, including Israeli soldiers who have served in the Israeli Defense Forces (IDF). Phase 2 clinical trials for MDMA as a safe and effective treatment for PTSD. Yet when we lean too heavily on the medical model to address mental health challenges, we often miss the root causes of a system of suffering. In this case, the PTSD is not individual pathology or sickness, rather it stems from the ongoingof Palestine.Psychedelics are not and never will be politically neutral: They are rooted in, inextricably tied to and . The use of psychedelics either support or upend the status quo, and the integrity of the psychedelic movement relies on human rights and to always be at the forefront of our work. I agree that everyone deserves healing: PTSD is painful, no matter who experiences it or what the cause is. 18-year old Israelis must serve in the military - they are forced to carry out state violence and clearly the mental health toll is devastatingly high. But
psychedelic healing must first and foremost be a tool to support the freedom of the oppressed - not a balm to soothe those who carry out oppression.
In a , a representative of the Charles and Lynn Schusterman Family Foundation, one of the partners of the MDMA clinical trials, stated: “A society is only as strong as how it cares for its most vulnerable communities. I am proud that Israel is leading the world in exploring new ways to support and treat people suffering from PTSD and psychiatric illnesses. The Compassionate Use program in Israel is an opportunity to
help high-risk populations
[emphasis mine], including IDF soldiers who have served their country, whose mental health needs are often overlooked and underserved [...] over 10% of the Israeli population experiences PTSD, and this figure increases significantly in regions frequented by rocket attacks. Military service is compulsory, and most families in Israel have histories of trauma and persecution.”The “vulnerable community” and “high-risk population” whose “” with “” that is mysteriously absent from the press release, however, are Palestinians. Today is the 72nd anniversary of (meaning “the catastrophe” in Arabic) commemorating the period of time when were dispossessed from their homes to form the state of Israel, more than 450 villages burned. Now in 2020, Palestinians still fight daily for the rights guaranteed to them .Major human rights organizations on the plight of the Palestinians: Israel subjects Palestinians to ongoing persecution that strips their right to personhood, freedom, health, and liberty. Gaza is the site of a and has been called the because in and out of the region, controlling and limiting the supply of , , , and . Israel severely restricts Palestinians’ and subjects them to ,, , , , , and . The has grown to millions of Palestinians - entire generations of families displaced from their homes. Israel enforces , with two very different systems for Jewish and non-Jewish people. I’ll note here that I’m a Jewish American who, like many of my peers, was raised to believe that Israel was a benevolent underdog.If those of us invested in the work of psychedelics ignore the political realities around psychedelic healing, we can become an accomplice to human rights abuses, helping the violent status quo to strengthen and persist. This is another way that the medical model fails us: As long as systems of oppression are firmly in place, there is an endless stream of “patients” seeking medicine to manage something that is much bigger than any one individual. As Jiddu Krishnamurti said, “It's no measure of health to be well adjusted to a profoundly sick society.”It’s also important to follow the money. Israel is deeply invested in becoming an entrepreneurial center of gravity with a booming that includes and businesses. Psychedelic investment by the state of Israel is inextricably tied to its economic interests: An emerging wave of psychedelic and see a tremendous (a for another day) and of course Israel wants to be on the cutting edge. Note that Israel is also of U.S. foreign assistance since World War II, currently receiving about $3.8 billion every year () specifically in military funding. In this way, Israel profits from instigating military violence and it profits from healing the trauma of violence.
They manufacture the illness and the cure.
It’s a compelling open question under what conditions could psychedelics help shift the minds and hearts of people who hoard resources, commit violence, or otherwise uphold oppression. But any project of that nature must be led by those most impacted by injustice, with a political framework that accurately portrays the political reality and power imbalance at play. And it must be accompanied by the understanding that the ultimate goal is to change the systemic conditions that cause suffering, not just to personally feel at peace amidst injustice.This comes at a time when Palestinians call on the world to support their fight to hold Israel accountable to international human rights law. This is the movement and it encompasses everything from to from companies that profit from the Israeli occupation. BDS is a form of non-violent protest notably fighting for freedom from apartheid. There is also a growing movement of allied who speak out and who refuse to serve as soldiers and execute the occupation. When individuals carry out oppression, everyone involved loses their humanity. I say this as a Jewish person who has seen Israel uphold the occupation in my name. It’s devastating to have your community face unspeakable, genocidal suffering only to turn around and become the violent oppressor. And as an American, I know that taxpayer money funds these catastrophic human rights violations. There aren’t enough psychedelics in the world to wash the blood off of our hands.It would be powerful to see commitments from people across the psychedelic field that support the Palestinian people in their struggle for justice. It is vital that psychedelic research teams , , and expand their scope beyond the medical model to really capture the full magnitude of potential psychedelic impact on the global majority. We must always keep our eye on the systemic conditions that cause human suffering because
psychedelics are not meant to heal us back into oppressive systems.
We must apply our psychedelic journeys to birth better worlds. As psychedelics often teach us, our fates are intertwined: Palestinian liberation makes us all more free.
A huge thank you to my creative collaborators Alex Bledsoe and Nikolitsa Paranomos for your support with this piece.
How I Ease my OCD and Anxiety with Psychedelics
How I Ease my OCD and Anxiety with Psychedelics
Publication date: 03-10-2020
Open full article in lightbox
Art by . Image description: Shadow of a person from behind standing on a grass and flower lined path with gold steps in a sea of blue glass overlooking purple mountains and a sunrise. By Amanda GelenderI have struggled with OCD and anxiety for about 25 years. My OCD has shapeshifted over time, camouflaging into each phase of my life, but the themes have remained pretty consistent through the years. At this point in my life, my OCD could perhaps best be described as meaning that while I have compulsions, obsessive and intrusive thought loops are the most debilitating aspects of my condition. At times, OCD fear loops have been so overwhelming that entire parts of my life shut down - for example, I stopped driving for years because I couldn’t shake the terrifying fear that I would accidentally hurt someone.I have been fortunate enough to work with many different healing modalities throughout my life, including talk therapy, community support networks, acupuncture, medications (), cannabis, peer-support group therapy, physical movement, nature, and creative practices. I have also worked extensively with psychedelics to manage my OCD, anxiety, and depression. While I don’t seek or expect a “cure” to my mental health challenges, LSD and psychedelic mushrooms are life changing tools to work through my fears and come to peace with myself, facilitating some of the most transformational healing work of my life.Working with psychedelics to support folks with OCD and anxiety is a topic of deep interest to me both personally and professionally: In addition to my own experiences, my work is to facilitate with psilocybin mushroom truffles. I’m not a doctor or therapist, I facilitate experiences as someone with extensive experience with psychedelics and a love for creating the conditions for others to benefit from them the way I have. Many of the people who reach out for sessions experience anxiety and/or OCD, so I’m frequently in conversation with folks about whether psychedelics may be helpful tools to support them. There are still many open questions about how and why psychedelics impact people the way they do - this is not merely a scientific inquiry, it is also political, philosophical, cultural, and spiritual. In this age of crumbling drug prohibition, western science is trying to catch up to what about the healing potential of entheogenic plant medicine. Researchers have only begun to scratch the surface on psychedelic applications for and , but so far are very promising. I’m confident that in the coming years, psychedelic medicine will become mainstream treatment for a broad range of mental and physical health challenges. We just have to keep our focus on access and , being wary of how these incredibly powerful tools may be and a for-profit medical system.In a neurological context, about classic psychedelics and the brain is that it temporarily quiets down the “default mode network,” a part of the brain that filters and communicates information between various regions. So when the default mode network goes off duty during a psychedelic trip, parts of the brain can communicate that don’t usually talk to each other and new neural connections . We suddenly have unfiltered access to a slew of information, memories, and feelings that are often difficult to tap into in our standard state of consciousness. It can help us feel what some call “ego dissolution,” a sensation that changes , which to the positive benefits of psychedelics. Below is of brain scans depicting the neural connections with psilocybin (image b) and a placebo (image a): Brain scans showing connectivity with psilocybin (right) and with a placebo (left). Credit: Petri et al./Proceedings of the Royal Society Interface But what does this mean on a practical level? Well, it’s different for everyone. I have found that in the psychedelic state it’s easier to go past the mind and work through trauma in my body. I can release control and explore my deepest fears and traumas at the root of my anxieties. I can hold myself with compassion and feel through repressed emotions, tapping into a sense of universal oneness and spiritual connection. I can feel tremendous joy, sorrow, rage, euphoria, and humility, a powerful emotional catharsis that cleans my pipes. In the time after a trip, there is often a window of that can particularly support folks with depression and anxiety - it often feels a bit easier to try new things and shake up old habits. I feel more present and aware of what I want. I feel re-energized, appreciative, and grounded. Ideas, fresh perspectives, and creativity comes more easily. My connections and community work deepens. All of these shifts help ease the daily struggle of anxiety.Of course when we ask a question like, “How can psychedelics help relieve anxiety?” we have to remember the context in which we attempt to heal: Racialized capitalism. We live under political systems that exacerbate and facilitate trauma and perpetual anxiety, particularly for Black and Brown people. It’s very hard to heal yourself in an environment that continues to inflict harm. So we have to remember that while mental health challenges can feel like individual plights, they are often not so much personal pathologies as they are natural ways of responding to our environment. While psychedelics are incredibly powerful tools for exploration and healing, to truly address the roots of mental health crises, our focus must always be on systemic level change.From what I have witnessed with clients, people heal differently with these tools and it can change over time. Some folks have a radical shift after a trip, others may have a more subtle shift or may not resonate with this modality at this point in their life. A trip that facilitates a strong sense of interconnectedness with the universe (ego “death” or dissolution) who struggle with depression and anxiety. But in my experience, ego dissolution isn’t a prerequisite for substantial healing with psychedelics. I like to remind clients that the wisdom from psychedelic sessions can come in many forms: Just because there may not be a stark, immediate shift after a trip doesn’t mean that important work isn’t being done. Rather than a silver bullet, I view psychedelic sessions as powerful steps on a healing and growth path. Each trip I shed another layer and go deeper - it’s a process that can take time. So while my work with psychedelics hasn’t eradicated my OCD or anxiety symptoms, the volume has turned down, and I have renewed mental, emotional, and spiritual fortitude to traverse challenges when they arise. A great example is my writing - OCD would want to block me from publishing this piece (“Have I checked it enough times to see if I said something incorrect? Will I accidentally cause damage with what I share?”...) but I move through the fear and publish anyway. It’s not that those voices aren’t there, it’s that they don’t drive and control my life the way they used to. In working with psychedelics through the years, I’ve become less fear-based. I feel more aligned and at peace with the natural ebb and flow of things.I have also found that psychedelics work well in partnership with other healing modalities. People who have healing practices in place before their trip often have an easier time integrating the lessons from psychedelic journeys. By the same token, psychedelics can enhance existing practices, helping people go deeper and unlock new levels in talk therapy, meditation, and artistic expression, for instance.
Trip Tips for Folks with OCD & Anxiety
The many unknowns of a psychedelic journey can be the perfect catalyst for worry, particularly for those of us with a proclivity towards looping, catastrophizing, and worst-case scenarios. It’s completely normal to be scared before a psychedelic journey - I was certainly terrified before my first psychedelic trip and I’m so grateful to have had thorough preparation and a supportive person there with me to help me feel safe in my exploration.A wide range of experiences are possible in a psychedelic journey and even healing trips can sometimes feel scary or even traumatic. In my experience, going through these dark places in psychedelic journeying can still bring great positivity, but only if the container around the trip is supportive. This is which found that the majority of people who have had challenging psychedelic mushroom experiences still said they were “‘meaningful’ or ‘worthwhile,’ with half of these positive responses claiming it as one of the ” To set yourself up for a safe and transformational session, it’s always wise to follow basic prep guidelines - access the medicine from a trusted and safe source (testing the substance if necessary), know a good starting dose, may affect your trip, prepare and feel as centered as possible before the journey (set), arrange for a safe and nourishing space (setting), have a person with you for support (sitter or guide), and allot time to process in the days following the session (integration). I actually think that a healthy mix of nervousness and excitement before a trip is a good thing: It demonstrates that you have reverence for how powerful a psychedelic teacher is and that it has the potential to significantly shift your life. But of course it’s best not to go into a trip feeling too anxious, so practice grounding yourself before the journey. And if you’re really struggling the days leading up to the trip - don’t push it. Check in with yourself and see if you want to postpone your trip or start with a lower dose. It’s also important to note that psychedelics aren’t for everyone and it can shift depending on what you’re going through. For instance, I don’t go on full dose trips when I am in a depressive crisis, a particularly bad OCD episode, or when I’m very stressed or overworked. I’ve found that these trips can be unnecessarily challenging or even temporarily damaging, so I wait until I feel a bit more stable to have a session. After your trip, be kind to yourself and take time to process in whatever ways feel most natural to you. It can be particularly helpful to write, draw, rest, and be in nature in the days following your journey. It’s normal to feel many things after a trip so let the changes unfold over time and don’t rush to make sense of everything. Be patient if changes don’t come right away and remember that for those of us who struggle with anxiety and OCD, just the act of releasing control and taking the leap into the psychedelic journey is a huge achievement.
8 Songs for Transformational Psychedelic Mushroom Experiences
8 Songs for Transformational Psychedelic Mushroom Experiences
Publication date: 02-27-2020
Open full article in lightbox
Digital drawing of purple, yellow and pink smoke flowing through broad green leaves. Art by Nikolitsa Paranomos.
By
While the impact of music on psychedelic sessions is currently an ongoing , music has been a powerful component of psychedelic journeying for centuries, rooted in indigenous, ceremonial practice with plant medicine. In the context of psychedelic mushroom journeying outside of a shamanistic practice, musical considerations are personal as well as cultural. Not everyone responds well to the most common types of music played in retreat and clinical settings - for instance, clients grappling with the impact of white supremacy on their psyches may be less likely to resonate with classical music that harkens back to colonization. “World” music selected without proper cultural context can miss the mark and feel exoticizing. We need more research focused on experiences of people of color from a wide range of backgrounds to really understand how music can foster breakthroughs in psychedelic sessions.At our in Amsterdam, we support people from many walks of life through legal, sliding-scale, private psychedelic mushroom experiences. Time and again, we’ve witnessed how the right songs played at the right time can facilitate tremendous breakthroughs in psychedelic sessions. We have an individualized approach to music selection: Rather than follow a set playlist, we live-DJ for our clients, pulling from our extensive catalogue of songs to support moment-to-moment flow. We also ask clients to send us music that holds particular significance for them: Peppering in these personal tracks during key moments creates an opportunity to process through emotions, memories, traumas, and relationships.Our individualized approach also means that as guides we are exposed to a steady stream of fresh musical tracks from our clients from around the world. I’ve pulled eight pieces of music from our library that we love to play during client sessions - enjoy! The Come Up
&
- -
The hypnotic, loving music of Beautiful Chorus is a staple for our sessions. Faith’s Hymn and the chakra tracks from their Resonance Meditation album create a soothing, womb-like atmosphere. These songs facilitate a warm, other-worldly invitation into the psychedelic journey. We often play these songs on loop in both the come up and the come down of a session. (Shout out to our collaborator Alex Bledsoe who put us on to their stunning music!)
- -
Radiohead guitarist Jonny Greenwood received an Oscar nomination for his original score for the 2017 film Phantom Thread and this particular track from the film is a go-to for when the trip begins to lift off. The rolling crescendos usher in a fresh, enchanting state of being to set the stage for the journey. The Peak
- -
We love to play this track during the transition from the come-up into the peak of the experience. It’s almost completely instrumental except for the mantra “let it go” spoken as the beat picks up. This song’s layered, hypnotic vibe combined with a powerful mantra of release supports breakthroughs at a time in a trip when surrendering is key.
- -
We were first introduced to Kamasi Washington by a jazz writer client who sent along some of his music for her session. We loved the tracks so much that we incorporated his work into our library. Integrity is hypnotic and layered, definitely worth repeating.
- -
This is a classic track by the legendary Nigerian Afrobeat artist Fela Kuti. It’s an intense, sweeping selection to experience on a psychedelic trip so we save it for the fervency of the peak. We’ve found this song to be a particularly strong choice for Black and Brown clients doing ancestral and work during their session.
- -
This beautiful 2016 track is gentle but rhythmic, invoking the feeling of riding a wave or moving through water. It can play on loop and doesn’t overwhelm the senses, guiding you through a psychedelic state with inspiration and ease. It’s also a wonderful track to create art with on a psychedelic journey. The Come Down
- -
This is one of our favorite songs to loop during the comedown of a psychedelic trip. KOKOROKO is a truly genius Afrobeat collective out of London whose music is at the same time calming and stirring. As clients float back to this plane from their session, the vibes of Abusey Junction are often a welcome homecoming.
-
As the revelations and breakthroughs of a trip are setting in after a full journey, this song brings a loving and poignant presence. It’s a great choice for when folks are coming more fully back into their bodies and can manage a track with lyrics. Nina Simone’s version of this song is a particularly compelling and beautiful choice, given her legacy as a and musical force of nature.We’re always creating new lists and would love to send them directly to you - to catch the vibe.
How Psychedelic Mushrooms Support Me
How Psychedelic Mushrooms Support Me
Publication date: 02-20-2020
Open full article in lightbox
Digital drawing of a blue mushroom with gold strands, circled by pastel painted green leaves. Artist:
By
This piece is my contribution to the #ThankYouPlantMedicine campaign to de-stigmatize and psychedelic plant medicine. From microdosing to full dose experiences, psilocybin “magic” mushrooms have supported me tremendously me over the years. I also work intentionally with cannabis, which continues to bring me healing and positive transformation. For context, I have struggled for many years with several mental health challenges including OCD, depression, and anxiety. I’ve been on prescription medications over the years and am currently on an SSRI . I’m from the Bay Area and live in the Netherlands where psilocybin is legal for purchase in the form of mushroom truffles. I’m the founder of a sliding-scale in Amsterdam - my team and I support people from around the world through psychedelic mushroom truffle sessions with the goal of helping to create a more just, equitable, and sustainable world. Through my own personal transformations and the many client sessions I’ve facilitated, I’ve seen first-hand how with supportive preparation (set) and environment (setting), psychedelic mushrooms have tremendous potential to support people in a multitude of ways (something that indigenous people have ). Learning to work with psychedelics has been an ongoing process: Along with euphoric and joyful moments in trips, I’ve also had very challenging experiences where I was grateful to have a nourishing environment and supportive person at my side. While psychedelics are not for everyone at all points in their lives, they are now a vital part of my wellness and social change work. They also complement and enhance the therapeutic benefits of my other healing modalities. I believe that psychedelic plant medicine, including psilocybin and cannabis, should be and widely accessible for people to grow and share in community. Our focus must always prioritize , , and over - a significant battle under racialized capitalism. But any movement to reduce individual pain has a responsibility to address the systemic causes of suffering. The rise of psychedelic medicine must include to address the generations of damage inflicted on Black and Brown communities through , , and the . The global struggle for indigenous rights is and to all plant medicine practice. I write my story about working with mushrooms in part because my whiteness shields me from impunity - I can speak openly about substance use with less risk than my friends of color. My ability to work with largely illegal medicines as openly as I do and with as little friction as I experience is a direct result of my whiteness - all of the times I have
not
been by police, for instance. I hope our collective stories shared today lead to positive, systemic change. Here are ways psilocybin mushrooms have supported me:
New Ways of Perceiving
In mushroom sessions, I can access fresh perspectives on all facets of life. It can sometimes feel like being given a universal key to explore every room in the house of . I can wander into any space and explore memories, desires, and fears in ways that often feel inaccessible in my standard state of consciousness. Heightened sensations and perceptive shifts in psychedelic sessions allow me to continually gain a deeper understanding of myself and the world around me. This is particularly helpful as someone who frequently experiences anxiety and depressive loops: A new mindset and path forward can mean . Everything I encounter during a psychedelic journey can teach me a lesson, a mindset that also serves me well in daily life. I marvel with profound curiosity and appreciation for everything around me, even if I don’t have language to describe its complexity.
Creative Flow
Mushrooms help me to create without self-censoring. I write and draw freely and unselfconsciously, focused on the joy and power of creating rather than the output. New ideas emerge organically. I deepen my appreciation for music, art, poetry, and natural beauty, as I can perceive these mediums with enhanced meaning and feeling. I gain more forgiveness and understanding for my own creative process, helping me release the shame of not producing “enough” or “better.”
Feel my feelings
Mushrooms help me to feel my feelings with depth and profundity - I often weep, rage, marvel, and burst into uncontrollable laughter. Accessing the entire emotional spectrum helps me to better understand and appreciate my multitudes. The catharsis of full, embodied emotional release on psychedelics has been tremendously healing. Psychedelics help me process through trauma not just cognitively but with my whole being (body, mind, spirit).Psychedelics let me access a well of inner wisdom which gives me a sense of safety, security, and groundedness in my daily life. In working with mushrooms and cannabis over the years, I now feel less resistance to change and more at ease in transition. Even though I have a long way to go in releasing my perfectionism and unnecessary fears,
it’s been a relief to feel more at peace with the natural ebb and flow of things - endings, beginnings, birth, life, death.
Embodiment
Mushrooms help me feel through pain and and programmed into my cells. I can work through and more easily release body shame. I can explore my embodied experience of gender and sexuality. I often experience a resounding, indescribable sense of somatic gratitude which spills into my daily life, relationships, and social change work in the days and weeks to come.
Deepened Connections
After sessions, I often have an enhanced desire for deep connection. I feel more present with myself and others, grateful for the time we have together. I‘m open to new, aligned connections. Because my sessions help me tune into my wants and needs, I feel less fear in sharing my truth and asserting boundaries. After sessions I often initiate uncomfortable conversations that I had been putting off or take the leap to do something I’ve been wanting to do but felt too afraid. I often emerge from trips revitalized, nourished, in deeper connection with those around me, and with a spark of optimism, which feels particularly important and elusive in these bleak political times.
Fuel to Imagine and Build a Better World
We still have a lot to learn about how psychedelics impact and . But I certainly see their radical potential. Mushrooms can help us imagine possibilities outside of dominant paradigms and systems: Tunnels to a better world. Mushrooms let us dissolve boundaries and borders, reminding us that all of our fates are intertwined. They can help us engender deep empathy for all living things, reconnecting us with our roots in the natural world. Psychedelics are not just tools for individual improvement, as asserted by the medical model and dominant neoliberal paradigms. Our collective challenges are systemic and our solutions must be as well. Psychedelics aren’t a substitute for structural change, but they can open us up to new ideas, connect us to our values, and re-energize us to fight for structural solutions, breathing new life into our social change work.As adrienne maree brown, author of , , “Where we are born into privilege, we are charged with dismantling any myth of supremacy. Where we are born into struggle, we are charged with claiming our dignity, joy and liberation.” I think psychedelics can support all sides of this work. For those who experience oppression - particularly Black and Brown folks - psychedelics can be an access point to feel tremendous freedom and healing from generations of racial trauma. They can usher in powerful joy, release, and ancestral connection. They can with the process of , feeling freedom, worth, and truth outside of systems of oppression. And for those with privilege, we can work with psychedelics to explore how to best leverage our resources and positionality for a more just world. Mushrooms can help us all to dream up a better society and then boost our momentum and capacity to actually build that world.
Explore All Things - Mind, Consciousness, Dimensionality, Identity, and Spirituality
Mushrooms give us an opportunity tap into the interconnectedness of all things, the expansiveness of our consciousness, and the energy flow of the universe. They provide direct access to spiritual planes and ancestral wisdom (one the reasons why by indigenous sacred use of mushrooms was unmediated access to the divine). Each trip, mushrooms reveal more data in an unlimited stream of channels, windows, mirrors, and portals. They help to continually pull away at a seemingly endless series of veils, opening access into facets of dimensionality, nonlinear time, and consciousness. Psychedelic exploration will continue to have a tremendous impact on what we know about existence and consciousness.With mushrooms I can deeply explore facets of my queerness, race, sexuality, and gender. I can melt walls I’ve built to shield and protect myself from pain. I can muster the courage to walk into the basement of my subconscious and see what I’ve been too afraid to look at - trauma, guilt, shame, death, failure, abuse, resentment, anxiety, sadness, uncomfortable truths. This work can be painful and exhausting, but it can also be gentle and fortifying. Each session I gain more embodied strategies to accept all parts of myself and traverse life’s challenges. It has been some of the most profound healing work of my life.
Q4 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Q4 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Publication date: 03-14-2023
Open full article in lightbox
On March 14, 2023, MAPS released a progress report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). . The post
Q4 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Big, if True: Did Australia Legalize MDMA and Psilocybin?
Big, if True: Did Australia Legalize MDMA and Psilocybin?
Publication date: 02-28-2023
Open full article in lightbox
Has Australia legalized MDMA and psilocybin?
No.
It’s not that simple.
The TGA in Australia only changed its policy to allow for the use of MDMA for PTSD and psilocybin for TRD by government-registered psychiatrists. No other psychedelic substances or mental health conditions are being considered at this time.
Will MDMA and psilocybin be available to just anyone?
No
. MDMA and psilocybin will only be prescribed by medical practitioners who are also Authorized Prescribers. Authorized Prescribers, must obtain written informed consent from each patient, arrange for supply of the drug, monitor the patient during and after treatment, and report any adverse events.
Will the Australian government be supplying MDMA and psilocybin?
No.
Prescribers will acquire MDMA and psilocybin from companies, called “sponsors,” seeking approval of the substances. Sponsors will monitor the use of the “unapproved” goods, and report adverse events and product defects to the TGA. Sponsors must also provide biannual reports to the TGA on drug supply.
Will MDMA and psilocybin be rescheduled in Australia?
Yes, but not by much.
MDMA and psilocybin will be reclassified in the Australian drug schedule from Schedule 9 to Schedule 8, but only for the purposes of the APS. Schedule 9 lists substances that have a high potential for misuse and abuse. In Schedule 8, both MDMA and psilocybin will be permitted for human therapeutic use but maintain restrictive regulatory controls on their availability., the , and have programs for psychedelic-assisted therapies to treat mental health conditions. These countries are allowing the use of “unapproved” (pre-approval) substances outside of clinical trials for people who are not responding to approved treatments for intractable conditions. This is commonly referred to as “compassionate use.” Distinctions in Australian MDMA and Psilocybin PolicyThe (TGA) in Australia recently announced a new policy allowing for the limited use of psychedelic-assisted therapies in the treatment of posttraumatic stress disorder (PTSD) and treatment-resistant depression (TRD) through an Scheme (APS). The news has been met with excitement around the world from drug policy reformers. We’ve received lots of questions about it, so we’ve put this policy decision in context to understand its possible impact.In, we wrote that because the US, Israel, and Canada have all permitted the use of some psychedelic(s) for what is often called “compassionate use,” Australia is the fourth nation to take comparable action. We use the umbrella term “compassionate use” because each national jurisdiction uses different processes and language to achieve similar outcomes: providing access outside of clinical trials to unapproved drugs, based on the existence of some evidence of efficacy and safety for patients with particularly intractable conditions or conditions not responsive to currently approved treatment options.Like the U.S. Controlled Substances Act, Australia’s drug control system includes schedules (from 1 to 9) for drugs with special rules governing their supply, distribution, prescription, and use. Unlike the United States, where Schedule 1 is the most restrictive, Australia’s is the opposite where 9 is the most restrictive. The TGA’s recent decision moves MDMA and psilocybin — solely for the purposes of the APS — from schedule 9 into schedule 8, which creates an opportunity for a prescriber to apply for permission to access the presently-unapproved drugs for specifically enumerated conditions (PTSD and treatment-resistant depression, respectively) for a certain class of patients. This scheme is related to (and often conflated in the media with) the Australian Special Access Scheme (SAS), which lets prescribers request permission to access an unapproved drug on a single, patient-by-patient basis. The single-patient SAS is comparable to Canada’s Section 56(1) exemption process whereby prescribers seek exemptions from certain drug controls to provide a single patient with an unapproved drug. For comparison, in the U.S. “compassionate use” is provided for on a limited basis via and schemes, with varying levels of regulatory involvement as well as burdens on the provider and supplier. In 2019, Israel’s Health Ministry allowed for compassionate use of MDMA, a policy change that permitted MAPS PBC to conduct part of its Phase 3 MDMA-assisted therapy for PTSD research there.Under the TGA APS for psilocybin and MDMA, interested psychiatrists will need to apply to become an authorized prescriber based on rigorous eligibility requirements, including the training in an acceptable treatment protocol (no protocols approved by the relevant authorities currently exist), and be approved by a Human Research Ethics Committee (HREC) or the College (the Australian equivalent of a Board) before being approved as an Authorized Prescriber. Importantly, psychiatrists who have been authorized to prescribe the substances under the AP scheme are required to comply with the relevant legislation of the state or territory in which they practice.It is unclear, this early on, what protocol characteristics may be required to approve an application. The relevant HREC’s and the TGA may require additional aspects, such as exhaustion of existing treatment options, to approve an authorization.In our experience, therapeutic support is a critical element of MDMA- or psilocybin-assisted therapy. We are eager to see how Australia’s researchers, regulators, and providers develop infrastructure for training and appropriate provision of care for patients who are eligible to access psilocybin or MDMA under the APS. We are encouraged by the TGA decision and are hopeful that it continues to work collaboratively with providers, manufacturers, and prospective patients to implement a safe, effective and successful program.
NOTE
The safety and efficacy of psychedelic-assisted therapies are currently under investigation. No psychedelic-assisted therapy has been approved by the FDA or other regulatory authorities; no therapy works for everyone; and all therapies, even in clinical settings, carry risks.The post
Big, if True: Did Australia Legalize MDMA and Psilocybin?
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Statement: Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme
Statement: Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme
Publication date: 02-03-2023
Open full article in lightbox
FOR IMMEDIATE RELEASE: February 3, 2023The Therapeutic Goods Administration (TGA) in Australia today that they will permit limited use of certain psychedelic-assisted therapies for the treatment of mental health conditions through the (SAS), a compassionate-use provision. As the funder and sponsor of the of a psychedelic-assisted therapy, MAPS is encouraged to see a fourth nation provide access to some psychedelic-assisted therapies. Australians who have endured long-standing psychological suffering will soon have the opportunity to consider emerging treatments backed by rigorous clinical research: MDMA-assisted therapy for PTSD, with two successful Phase 3 studies, and psilocybin-assisted therapy for treatment-resistant depression, currently in Phase 2 clinical trials. Australia’s policy change is one that every country should consider: suffering people, regardless of nationality, need more opportunities to access novel treatments. We hope that this announcement will encourage more international discussion and collaboration towards access to psychedelic therapies and comprehensive drug policy reform.
, Founder and Executive Director of MAPS
Following , the , and , Australia is now the fourth government agency to enact a compassionate use program for psychedelic-assisted therapies to treat mental health conditions. Beginning July 1, 2023, psychiatrists in the will be permitted to administer psychedelic-assisted therapies in controlled clinical settings. Among other safety constraints, the new TGA regulations require that Authorized Prescribers obtain informed consent from the patient, are approved by an ethics committee, and “have the training and expertise appropriate for the condition being treated and the proposed use of the product.”
NOTE
The safety and efficacy of psychedelic-assisted therapies are currently under investigation. No psychedelic-assisted therapy has been approved by the FDA or other regulatory authorities; no therapy works for everyone; and all therapies, even in clinical settings, carry risks.
ABOUT
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world through its wholly-owned subsidiaries and . Since MAPS was founded, philanthropic donors and grantors have given more than $140 million for psychedelic and marijuana research and education. MAPS has earned both the and a.### Keep Reading…The post
Statement: Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
FDA Provides Additional Guidance for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
FDA Provides Additional Guidance for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Publication date: 01-20-2023
Open full article in lightbox
On January 19, 2023, the FDA advised MAPS that cannabis used in clinical trials is defined as a drug product, rather than a botanical raw material, for the purposes of microbiological testing acceptance criteria. . The FDA additionally requested protocol modifications related to effect size and one additional CAPS-5 assessment. MAPS has requested the FDA lift the clinical hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2).
MJP2_CommentsOnProtocol
The post
FDA Provides Additional Guidance for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
MDMA Therapy Training Program Update: January 2023
MDMA Therapy Training Program Update: January 2023
Publication date: 01-18-2023
Open full article in lightbox
The MDMA Therapy Training Program is not accepting applications at this time. Practitioners interested in learning more about the MDMA Therapy Training Program and future education opportunities can sign up for the to receive updates.
Consultation Program Update
Throughout January and February of 2023, the Consultation Team is running a 30-hour Associate Consultant Training program with the goal of having 11 additional Consultants to help support supervision efforts on our clinical trials. These Consultants will help oversee the Clinical Experience requirement for the MDMA Therapy Training Program. The post
<strong>MDMA Therapy Training Program Update: January 2023</strong>
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
Publication date: 01-05-2023
Open full article in lightbox
MAPP2, the second Phase 3 trial of MDMA-assisted therapy, treated 104 participants living with PTSD with either MDMA-assisted therapy or placebo with therapy
The results confirmed findings from MAPP1; no serious adverse events were observed among the participants
In a first for psychedelic-assisted therapy trials, more than half of MAPP2 participants
The nonprofit ’ (MAPS) clinical research program has achieved an important milestone: a successful confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD). The clinical research program that began in 1992 has been sponsored by the nonprofit MAPS and funded through philanthropic donations. Since 2014, (MAPS PBC), a wholly-owned subsidiary of MAPS, has administered the trials. When I first articulated a plan to legitimize a psychedelic-assisted therapy through FDA approval, many people said it was impossible. Thirty-seven years later, we are on the precipice of bringing a novel therapy to the millions of Americans living with PTSD who haven’t found relief through current treatments. The impossible became possible through the bravery of clinical trial participants, the compassion of mental health practitioners, and the generosity of thousands of donors. Today, we can imagine that MDMA-assisted therapy for PTSD may soon be available and accessible to all who could benefit.
, Founder and Executive Director of MAPS
The full data from , expected to be published in a peer-reviewed journal later this year, will support MAPS PBC’s new drug application to be filed with the U.S. Food and Drug Administration (FDA). By 1985, MDMA had been legally used in therapy treatments for a decade, with a growing body of promising anecdotal reports supporting its use. However, increasing social use led the Drug Enforcement Agency to criminalize the use and possession of MDMA that year. In 1986, Dr. Doblin founded MAPS to fund and facilitate research into the potential of psychedelic-assisted therapies; educate the public about psychedelics for medical, social, and spiritual use; and advocate for drug policy reform. A major milestone was reached in 2021 when the positive results of the first Phase 3 trial, .MAPP1 and MAPP2, the only completed Phase 3 trials of a psychedelic-assisted therapy, were conducted at 15 sites in the US, Canada, and Israel. Today, Phase 2 trials are being planned or conducted evaluating MDMA-assisted therapies for conditions closely related to PTSD, such as and . Trials of other therapies in combination with MDMA are being planned or conducted, such as and . These additional Phase 2 trials will determine if MDMA-assisted therapies may be effective for other conditions or with other treatment modalities commonly used to address PTSD.
NOTE
The safety and efficacy of psychedelic-assisted therapies are currently under investigation. No psychedelic-assisted therapy has been approved by the FDA or other regulatory authorities; no therapy works for everyone; and all therapies, even in clinical settings, carry risks.
ABOUT
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the world’s most advanced psychedelic therapy research through its wholly-owned subsidiaries and . Since MAPS was founded, philanthropic donors and grantors have given more than $140 million for psychedelic and marijuana research and education. MAPS has earned both the and a .### Keep Reading…
Why is diverse representation important in clinical trials?
If participants in clinical trials mostly represent similar populations, it can be difficult to ensure treatments will be safe and effective for a broad population. This is easy to understand with age: because adolescents and children may react differently to medications or dosages, Congress passed a law that requires some FDA-approved drugs to be tested separately in adolescents and children
after
they are proven safe and effective for adults. In clinical trials for PTSD treatments, it is particularly important that researchers strive to include people of color and LGBTQI+ individuals, who are more likely to develop PTSD — but less likely to receive a diagnosis or treatment.
Read more:
What is MDMA-assisted therapy?
MDMA-assisted therapy for PTSD is an integrative treatment delivered by two specially trained behavioral health professionals. It consists of four ninety-minute preparation sessions and three eight-hour medication sessions, each followed by three ninety-minute integration sessions.
Read more:
The post
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Give the Gift of Healing: Donate to Psychedelic Therapy this December 2022
Give the Gift of Healing: Donate to Psychedelic Therapy this December 2022
Publication date: 12-20-2022
Open full article in lightbox
For the past 36 years, we’ve been working tirelessly towards making MDMA-assisted therapy a legal treatment option for PTSD.
,
which means
our
psychedelic-assisted therapy research is crucial – this novel treatment could alleviate trauma so people can heal and reconnect with themselves and others.
This holiday season,
Donate Now
Your support makes our groundbreaking research possible.
We hope you will give the gift of healing and create hope for a brighter future for millions of people. The post
Give the Gift of Healing: Donate to Psychedelic Therapy this December 2022
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
FDA Continues Clinical Hold for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
FDA Continues Clinical Hold for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Publication date: 12-17-2022
Open full article in lightbox
On December 16, 2022, the FDA advised MAPS that the Partial Clinical Hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) would be continued due to “insufficient information to assess risks to human subjects.” MAPS is preparing a response to the the Clinical Hold issues and additional non-Clinical Hold issues the FDA has identified. .The post
FDA Continues Clinical Hold for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Policy and Advocacy Update: December 2022
Policy and Advocacy Update: December 2022
Publication date: 12-16-2022
Open full article in lightbox
There were many substantial legislative moments for psychedelics in 2022. States and municipalities across the country continue to seriously consider making changes to their laws governing psychedelic substances.Late this year, we received encouraging national news when . We celebrated the formation of the Congressional Psychedelics Advancing Clinical Treatments (PACT) Caucus, led by Representatives Lou Correa (D-CA) and Jack Bergman (R-MI).This caucus will consist of bipartisan members of Congress committed to “addressing ways to alleviate the national mental health crisis through psychedelic science and research.” PACT looks to advance research into the therapeutic use of psychedelic compounds and ensure any FDA-approved psychedelic-assisted therapies are available to those in need, in accordance with the law.
“We are encouraged that Representatives Correa and Bergman are taking significant steps to bring the conversation about psychedelic research and therapy to Congress. This initiative will build upon the growing national interest in the potential for psychedelic care modalities to be incorporated into healthcare. We look forward to working with members of the caucus to educate their colleagues to replace drug war rhetoric with science, evidence, and compassion.”
– , Director of Policy & Advocacy, MAPS
The PACT Caucus will not be offering recommendations on decriminalization, legalization, rescheduling or de-scheduling psychedelic substances. Rather, the goals of this caucus are to:Increase awareness of psychedelic-assisted therapies among members of Congress and their staffs, Support increases in federal funding for psychedelic scienceExamine regulatory impediments to psychedelic researchThe post
Policy and Advocacy Update: December 2022
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
MDMA Therapy Training Program Update: December 2022
MDMA Therapy Training Program Update: December 2022
Publication date: 12-14-2022
Open full article in lightbox
The MAPS PBC Training Team had a robust and fulfilling year launching newly designed education experiences, including a weeklong in-person retreat.The retreats were a learning journey for staff and trainees alike, offering scientific and therapeutic education from experienced lead trainers and assistant trainers who have worked on the MAPS-sponsored MDMA-assisted therapy clinical trials, experiential activities that put skills into practice, exploration through art, music, and self-reflection, and building a joyous education community. In 2022, the MDMA Therapy Training Program educated 360 practitioners across six cohorts as well as an additional 500 practitioners through collaborations with organizations such as the California Institute of Integral Studies, Naropa University, and the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research. With the support of donors, the expanded Health Equity Leadership Program for Practitioners awarded over $500k to 130 recipients who will help shape a modality that can reach the communities that need it most. The scholarship recipients identified as Black, Indigenous, and People of Color (BIPOC) (86%), LGBTQIA+ (54%), Transgender/Non-Binary/Two-spirit (13%), and people with disabilities (13%). We are grateful to all the practitioners and educators that were willing to give their time and presence to being a part of the MDMA Therapy education community. A special thanks to the teaching staff who joined us on this adventure and made 2022 so successful and rewarding: Marcela Ot’alora G.; Bruce Poulter; Michael Mithoefer; Annie Mithoefer; Keren Tzarfaty; Ido Siemion; Brooke Balliett; Philip Lister; Jennifer Jones; Michael Alpert; Chris Stauffer; Sara Gael-Giron; Nicole Sylvestre; Genesee Herzberg; Harvey Schwartz; Veronika Gold; Jason Butler; Joanna Simundic; Eric Sienknecht; Cristie Strongman; Evan Sola; Susan Walker; Elizabeth Call; Chantelle Thomas; Chistopher Nicholas; Andrea Rosati; Joseph McCowan; Paul Uy; Cheryl Breault; Yevgeniy Gelfand; Wende Reynolds; Kelley O’Donnell; Anne Wagner; Kevin Lutz; José Mata; Paulo Rebello; Amy Lehrner; Miryam Sperka; Lauren Lepow; Laura Pratchett; Mustafa Haznedar The MDMA Therapy Training Program is not accepting applications at this time. Practitioners interested in learning more about the MDMA Therapy Training Program and future education opportunities can sign up for the to receive updates. The post
MDMA Therapy Training Program Update: December 2022
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Latest Publications
–
Scientific literature 2020/2021
pulls refs test
References 2021
Importing BibTeX data...
0%
Contact
–
Get in touch…
pulls refs test
Get in touch...
Contact Dr. Christopher B. Germann
transmissions@psychedelic-lab.com
Your name
Your email
Subject
Your message
Please prove you are human by selecting the
Cup
.
Δ
Open form in lightbox window
Search
–
Intelligent search function
Intelligent Boolenan Search function (auto-completion)
Generic selectors
Exact matches only
Exact matches only
Search in title
Search in title
Search in content
Search in content
Search in excerpt
Search in posts
Search in posts
Search in pages
Search in pages
Search in posts
Search in posts
Search in pages
Search in pages
Search in posts
Search in posts
Search in pages
Search in pages
BTCEUR Chart
von TradingView
Top